Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Focal Segmental GlomerulosclerosisMinimal Change Disease3 moreTo evaluate the safety, efficacy and tolerability of sparsentan oral suspension and assess changes in proteinuria after once-daily dosing over the 108-week treatment period.
Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyThis is a phase 3 study to evaluate effects on proteinuria and glomerular filtration rate of sibeprenlimab 400 mg subcutaneously (s.c.) Q 4 weeks in adults with IgAN who are receiving maximally tolerated standard-of-care therapy.
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease...
Diabetic Kidney DiseaseIgA NephropathyThis is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of SC0062 capsule in patients with chronic kidney disease (diabetic kidney disease and IgA nephropathy)with albuminuria compared to matching placebo.
A Study of Telitacicept in Patients With Primary IgA Nephropathy
IgA NephropathyThe purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy.
A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin...
Primary IgA NephropathyThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RO7434656, a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
Bortezomib for Treating Glomerular Diseases
BortezomibGlomerulonephritis4 moreBortezomib is a proteasome inhibitor that inhibits autoantibody production, and reduces podocyte damage and mesangial hyperplasia caused by NF-κB activation in the kidney. Literature has reported that bortezomib can achieve a complete response rate of up to 38% in the treatment of glomerular diseases, but its safety and effectiveness remain to be assessed for the Chinese demographic. This study attempts to explore a new treatment plan for glomerular disease by observing the therapeutic effect of bortezomib on glomerular disease.
Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
Immunoglobulin A NephropathyThis is a phase 2/3 open-label study to evaluate the long-term safety, tolerability, and efficacy of sibeprenlimab administered subcutaneously (SC) in subjects with IgAN.
SodiUm Restriction by Behavioral Intervention
IgA NephropathyThe aim of this study is to evaluate the effects and efficacy of dietary sodium restriction by mean of a new healthcare approach in patients with immunoglobulin A nephropathy. The test persons in the intervention group are actively supported to adhere to a restricted sodium diet with a structured education program in combination with regular sodium excretion monitoring.
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy...
Immunoglobulin A NephropathyTo determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202)...
Immunoglobulin A (IgA) NephropathyRandomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN